Overview
The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in the body, and how effective it is in treating cancer. 131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum.
Eligibility
Inclusion Criteria:
- Have the diagnosis of DSRCT confirmed at MSKCC
- Age >1 year and able to cooperate with radiation safety restrictions during therapy period.
- Prior to intraperitoneal catheter placement
- At least 1 weeks must have elapsed since prior chemotherapy
- At least 2 weeks must have elapsed since biologic therapy
- Toxicities of prior therapy must have resolved to grade 1 or less or to the patient's baseline
At the completion of surgery, patients must fulfill all of the additional following
criteria:
- Have no definitive radiological evidence of disease active in liver or outside the
abdomen/pelvic OR have had GTR of this disease at the time of catheter placement
Exclusion Criteria:
- Prior progression of disease
- Prior hypothermic intraperitoneal chemotherapy (HIPEC)
- Cardiac, pulmonary, and neurologic toxicity should be grade 1 or less per NCI CTC
version 5
- Renal, gastrointestinal, and hepatic, toxicities should all be grade 2 of less (per
NCI CTC version 5)
- History of allergy to mouse proteins
- Patients with grade 4 hypersensitivity reaction to radiolabeled iodine